Skip to content

Study · Ex vivo tissue · 2024

2 results

Development of a defibrinated human blood hemolysis assay for rapid testing of hemolytic activity compared to computational prediction.

Carpenter AM, van Hoek ML

Journal of immunological methods9 Apr 2024Cited by 9 (Europe PMC)

PMID38604530 (opens in a new tab)DOI10.1016/j.jim.2024.113670 (opens in a new tab)PepBankPUB-38604530
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In human red blood cells collected in EDTA, LL‑37 showed high hemolytic activity.

    In plain wordsIn lab tests, LL‑37 broke open a lot of human red blood cells collected in EDTA.

    Peptide
    LL-37
    Outcome
    Not applicableHemolytic activity of LL-37 on EDTA red blood cells
    Study

    humann: not reported in source

    Human red blood cells collected in EDTA
    Outcome group
    Infection and antimicrobial activity · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Starting with an observation of high hemolytic activity of LL-37 peptide against human red blood cells that were collected in EDTA, we explored alternative approaches to develop a more robust, accurate and simple hemolysis assay using defibrinated human blood.

Studies that did not test the peptide alone1

In this study, LL-37 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LL-37.

  1. 02LabNot a test of LL-37 aloneEx vivo tissueOther

    In an assay-development study that began with LL‑37, defibrinated and EDTA-treated human red blood cells differed significantly in sensitivity in a hemolysis assay.

    In plain wordsIn lab tests, defibrinated and EDTA-treated human red blood cells differed in sensitivity in a hemolysis assay that began with LL‑37.

    Peptide
    LL-37
    Outcome
    Not applicableAssay sensitivity: defibrinated versus EDTA red blood cells
    Study

    humann: not reported in source

    Defibrinated and EDTA human red blood cells
    Outcome group
    Infection and antimicrobial activity · Pharmacology

    Source sentences

    Summary
    Starting with an observation of high hemolytic activity of LL-37 peptide against human red blood cells that were collected in EDTA, we explored alternative approaches to develop a more robust, accurate and simple hemolysis assay using defibrinated human blood. We found significant differences betwee…

    In this study, LL-37 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LL-37.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.